designing therapeutic humanised antibodies from your monoclonals

Antibody humanization

You have a target-specific, high affinity, rodent monoclonal antibody and would like to generate a therapeutic from it.   We will help you achieve this aim using the established classical methods, which have been used for most humanised antibodies in the clinic.

We design humanized antibodies from xenogeneic monoclonals.  Using the antibody engineering skills and experience of Scientific Founders Tarran Jones and David Williams, DaTaMabs provides a royalty-free service customised  to meet your individual needs.

extensive Know-how

The DaTaMabs team draws on 40 man-years of know-how and experience in the genetic manipulation and recombinant expression of therapeutic antibody candidates to generate your humanized antibodies. 

support at every step

DaTaMabs provides ongoing support through expression, testing, polishing and selection, enabling you to generate world-class humanized antibodies.

optional extras

We have well-developed relationships with laboratory-based service providers to provide all necessary practical capabilities, if required.

an impressive track record

The Founders of DaTaMabs have successfully humanized over 40 therapeutic antibody candidates in commercial collaborations with more than 20 biotech and pharma companies.  These projects led to the development of more than 10 clinical candidates, most of which are still in clinical trials.

four designs won market approval

There are now four humanized antibodies that were created by our design team which have achieved market approval. Two are already blockbuster drugs treating autoimmune diseases worldwide, whilst the latter two obtained regulatory approval this year. Significantly, these include a PD1-targeting antibody which is widely expected to be a “game-changer” in cancer therapy.

the leading technology

DaTaMabs gives  you access to the original, clinically-proven antibody humanization technology known as CDR grafting. This process reliably removes immunogenicity issues whilst retaining potency and specificity. It has been validated in over 200 clinical candidates and 18 regulatory- approved humanized antibodies worldwide.